137 related articles for article (PubMed ID: 20181162)
21. Hydroxychloroquine augments early virological response to pegylated interferon plus ribavirin in genotype-4 chronic hepatitis C patients.
Helal GK; Gad MA; Abd-Ellah MF; Eid MS
J Med Virol; 2016 Dec; 88(12):2170-2178. PubMed ID: 27183377
[TBL] [Abstract][Full Text] [Related]
22. Interstitial pneumonitis during combination therapy with interferon-alpha and ribavirin in a patient with chronic Hepatitis C.
Rothfuss KS; Bode JC
Z Gastroenterol; 2002 Sep; 40(9):807-10. PubMed ID: 12215950
[TBL] [Abstract][Full Text] [Related]
23. [Side effect of pegylated-interferon treatment in chronic C hepatitis: agranulocytosis].
Halász T; Farkas A; Tolvaj G; Horváth G
Orv Hetil; 2006 Feb; 147(7):321-4. PubMed ID: 17489160
[TBL] [Abstract][Full Text] [Related]
24. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.
Bronowicki JP; Ouzan D; Asselah T; Desmorat H; Zarski JP; Foucher J; Bourlière M; Renou C; Tran A; Melin P; Hézode C; Chevalier M; Bouvier-Alias M; Chevaliez S; Montestruc F; Lonjon-Domanec I; Pawlotsky JM
Gastroenterology; 2006 Oct; 131(4):1040-8. PubMed ID: 17030174
[TBL] [Abstract][Full Text] [Related]
25. Cost Effectiveness of Daclatasvir Plus Asunaprevir Therapy for Chinese Patients with Chronic Hepatitis C Virus Genotype 1b.
Liu Y; Wang Z; Tobe RG; Lin H; Wu B
Clin Drug Investig; 2018 May; 38(5):427-437. PubMed ID: 29417464
[TBL] [Abstract][Full Text] [Related]
26. [Importance of adherence for efficacy of hepatitis C combined therapy].
Nožić D; Delić D; Božić M; Fabri M; Svorcan P; Konstantinović L
Srp Arh Celok Lek; 2013; 141(7-8):507-10. PubMed ID: 24073558
[TBL] [Abstract][Full Text] [Related]
27. Acute inflammatory demyelinating polyneuropathy after treatment with pegylated interferon alfa-2a in a patient with chronic hepatitis C virus infection: a case report.
Lahbabi M; Ghissassi M; Belahcen F; Ibrahimi SA; Aqodad N
J Med Case Rep; 2012 Sep; 6():278. PubMed ID: 22947101
[TBL] [Abstract][Full Text] [Related]
28. [Clinical features of interstitial pneumonitis due to interferon alpha therapy for chronic hepatitis C].
Ji FP; Li ZX; Deng H; Xue HA; Liu Y; Li M
Nan Fang Yi Ke Da Xue Xue Bao; 2009 Apr; 29(4):667-70. PubMed ID: 19403391
[TBL] [Abstract][Full Text] [Related]
29. Interstitial pneumonia associated to peginterferon alpha-2a: A focus on lung function.
Cortés-Telles A
Lung India; 2016; 33(2):228-31. PubMed ID: 27051119
[TBL] [Abstract][Full Text] [Related]
30. Simeprevir with peginterferon and ribavirin induced interstitial pneumonitis: first case report.
Tamaki K; Okubo A
World J Gastroenterol; 2015 Jan; 21(3):1009-13. PubMed ID: 25624738
[TBL] [Abstract][Full Text] [Related]
31. Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients.
Laguno M; Cifuentes C; Murillas J; Veloso S; Larrousse M; Payeras A; Bonet L; Vidal F; Milinkovic A; Bassa A; Villalonga C; Pérez I; Tural C; Martínez-Rebollar M; Calvo M; Blanco JL; Martínez E; Sánchez-Tapias JM; Gatell JM; Mallolas J
Hepatology; 2009 Jan; 49(1):22-31. PubMed ID: 19085908
[TBL] [Abstract][Full Text] [Related]
32. Pleural effusion associated with pegylated interferon alpha and ribavirin treatment for chronic hepatitis C.
Arora A; Vargas L; Kuzniar TJ
J Hosp Med; 2009 Sep; 4(7):E45-6. PubMed ID: 19753589
[TBL] [Abstract][Full Text] [Related]
33. Pegylated interferon alpha-2b, ribavirin and amantadine for chronic hepatitis C.
Younossi ZM; McCullough AC; Barnes DS; Post A; Ong JP; O'Shea R; Martin LM; Bringman D; Farmer D; Levinthal G; Mullen KD; Carey WD; Tavill AS; Ferguson R; Gramlich T
Dig Dis Sci; 2005 May; 50(5):970-5. PubMed ID: 15906777
[TBL] [Abstract][Full Text] [Related]
34. Fatal cardiomyopathy associated with pegylated interferon/ribavirin in a patient with chronic hepatitis C.
Condat B; Asselah T; Zanditenas D; Estampes B; Cohen A; O'Toole D; Bonnet J; Ngo Y; Marcellin P; Blazquez M
Eur J Gastroenterol Hepatol; 2006 Mar; 18(3):287-9. PubMed ID: 16462543
[TBL] [Abstract][Full Text] [Related]
35. [Results of pegylated interferon and ribavirin for the treatment of chronic hepatitis C in clinical practice: a 5-year experience].
Vergara M; Gallach M; Dalmau B; Gil M; Miquel M; Rudi N; Gavarro A; Cebollero A; Masip M; Real J
Gastroenterol Hepatol; 2008 May; 31(5):274-9. PubMed ID: 18448055
[TBL] [Abstract][Full Text] [Related]
36. Neutralizing antibodies to interferon-α and circulating interferon in patients with chronic hepatitis C non-responding to pegylated interferon plus ribavirin re-treated by pegylated interferon-α-2a and ribavirin (ANRS HC16 GAMMATRI substudy).
Halfon P; Pérusat S; Bourlière M; Bronowicki JP; Trimoulet P; Benhamou Y; Leroy V; Marcellin P; Foucher J; Penaranda G; Chêne G; Couzigou P;
J Med Virol; 2010 Dec; 82(12):2027-31. PubMed ID: 20981789
[TBL] [Abstract][Full Text] [Related]
37. Cutaneous Sarcoidosis: An Uncommon Side Effect of Pegylated Interferon and Ribavirin Use for Chronic Hepatitis C.
Martins EV; Gaburri AK; Gaburri D; Sementilli A
Case Rep Gastroenterol; 2009 Nov; 3(3):366-371. PubMed ID: 21103255
[TBL] [Abstract][Full Text] [Related]
38. Autoimmune Hepatitis Triggered by Treatment With Pegylated Interferon α-2a and Ribavirin for Chronic Hepatitis C.
Rathi C; Pipaliya N; Choksi D; Parikh P; Ingle M; Sawant P
ACG Case Rep J; 2015 Jul; 2(4):247-9. PubMed ID: 26203454
[TBL] [Abstract][Full Text] [Related]
39. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.
Jacobson IM; Dore GJ; Foster GR; Fried MW; Radu M; Rafalsky VV; Moroz L; Craxi A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Scott J; Sinha R; Beumont-Mauviel M
Lancet; 2014 Aug; 384(9941):403-13. PubMed ID: 24907225
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
